|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
A myc tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a myc-tag allows one to follow the protein with an antibody against the Myc epitope. Examples are cellular localization studies by immunofluorescence or detection by Western blotting.
The peptide sequence of the myc-tag is: N-EQKLISEEDL-C (1202 Da). It can be fused to the C-terminus and the N-terminus of a protein. It is advisable not to fuse the tag directly behind the signal peptide of a secretory protein, since it can interfere with translocation into the secretory pathway.
|大鼠 Apolipoprotein H/APOH 基因ORF全长cDNA克隆(表达载体), C-GFPSpark 标签||RG80701-ACG|
|大鼠 Apolipoprotein H/APOH 基因ORF全长cDNA克隆(表达载体), C-OFPSpark 标签||RG80701-ACR|
|大鼠 Apolipoprotein H/APOH 基因ORF全长cDNA克隆(表达载体), C-Flag 标签||RG80701-CF|
|大鼠 Apolipoprotein H/APOH 基因ORF全长cDNA克隆(表达载体), C-His 标签||RG80701-CH|
|大鼠 Apolipoprotein H/APOH 基因ORF全长cDNA克隆(表达载体), C-Myc 标签||RG80701-CM|
|大鼠 Apolipoprotein H/APOH 基因ORF全长cDNA克隆(表达载体), C-HA 标签||RG80701-CY|
|大鼠 Apolipoprotein H/APOH 基因ORF全长cDNA克隆(表达载体), N-Flag 标签||RG80701-NF|
|大鼠 Apolipoprotein H/APOH 基因ORF全长cDNA克隆(表达载体), N-His 标签||RG80701-NH|
|大鼠 Apolipoprotein H/APOH 基因ORF全长cDNA克隆(表达载体), N-Myc 标签||RG80701-NM|
|大鼠 Apolipoprotein H/APOH 基因ORF全长cDNA克隆(表达载体), N-HA 标签||RG80701-NY|
|大鼠 Apolipoprotein H/APOH 基因ORF全长cDNA(克隆载体)||RG80701-U|
|大鼠 Apolipoprotein H/APOH 基因ORF全长cDNA克隆(表达载体)||RG80701-UT|
Apolipoprotein H (APOH), also known as Beta-2-glycoprotein 1, Activated protein C-binding protein, B2GPI, and B2G1, is a glycoprotein synthesized by liver cells and it is present in the blood associated with plasma lipoproteins. It is an essential cofactor for the binding of certain antiphospholipid antibodies (APA) to anionic phospholipid. APOH binds to various kinds of negatively charged substances such as heparin, phospholipids, and dextran sulfate. APOH may prevent activation of the intrinsic blood coagulation cascade by binding to phospholipids on the surface of damaged cells. APOH appears to completely inhibit serotonin release by the platelets and prevents subsequent waves of the ADP-induced aggregation. The activity of APOH appears to involve the binding of agglutenating, negatively charged compounds, and inhibits agglutenation by the contact activation of the intrinsic blood coagulation pathway. APOH causes a reduction of the prothrombinase binding sites on platelets and reduces the activation caused by collagen when thrombin is present at physiological serum concentrations of APOH suggesting a regulatory role of APOH in coagulation. APOH plasma concentrations are strongly associated to metabolic syndrome alterations and vascular disease in type 2 diabetic and could be considered as a clinical marker of cardiovascular risk. APOH is found on several classes of lipoproteins, and is involved in the activation of lipoprotein lipase in lipid metabolism. This single-chain glycoprotein also has been implicated in several physiologic pathways including coagulation and the production of hypertension, which are related to the pathogenesis of primary cerebral hemorrhage (PICH).